{
    "clinical_study": {
        "@rank": "53844", 
        "brief_summary": {
            "textblock": "To evaluate the safety and immune response of 100 mcg Env 2-3 antigen administered on days\n      0, 30, 180, and 365.\n\n      Preliminary immunologic data from protocol VEU 005B show evidence of the development of\n      functional antibodies in the form of increased peptide binding and development of\n      neutralizing antibodies. Evaluation of an antigen dose having potentially greater\n      immunogenicity is therefore of particular interest."
        }, 
        "brief_title": "A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59", 
        "completion_date": {
            "#text": "May 1992", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Preliminary immunologic data from protocol VEU 005B show evidence of the development of\n      functional antibodies in the form of increased peptide binding and development of\n      neutralizing antibodies. Evaluation of an antigen dose having potentially greater\n      immunogenicity is therefore of particular interest.\n\n      Twelve healthy volunteers receive injections of 100 mcg Env 2-3 in MF59 emulsion and two\n      volunteers receive MF59 only on days 0, 30, 180, and 365. Follow-up continues for 6 months\n      after the last injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Subjects are:\n\n          -  Normal, healthy adults (by history and physical examination) who fully comprehend the\n             purpose and details of the study.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Subjects with the following conditions or symptoms are excluded:\n\n          -  Positive syphilis serology (such as VDRL) unless positive test is due to a documented\n             clinical event that occurred and was treated 5 or more years prior to enrollment.\n\n          -  Circulating hepatitis B antigenemia.\n\n        Subjects with the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, or autoimmune disease.\n\n          -  Evidence of depression or under treatment for psychiatric problems during the past\n             year.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Immunosuppressive medications.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Blood transfusions or cryoprecipitates within the past 6 months.\n\n        Identifiable high-risk behavior for HIV infection, including:\n\n          -  history of intravenous drug use; syphilis, gonorrhea, or any other sexually\n             transmitted diseases (including chlamydia or pelvic inflammatory disease) in the last\n             6 months; more than two sexual partners, or sexual contact with a high-risk partner,\n             in the preceding 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000632", 
            "org_study_id": "AVEG 005C", 
            "secondary_id": "10548"
        }, 
        "intervention": {
            "intervention_name": "Env 2-3", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Adjuvants, Immunologic"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Vaccines, Synthetic", 
            "Drug Evaluation", 
            "Adjuvants, Immunologic", 
            "AIDS Vaccines", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "April 27, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Univ. Hosp. AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981050371"
                    }, 
                    "name": "UW - Seattle AVEG"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59", 
        "overall_official": {
            "last_name": "Dolin R", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "9486388", 
                "citation": "Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. Clin Exp Immunol. 1998 Feb;111(2):243-50."
            }, 
            {
                "PMID": "8744579", 
                "citation": "Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000632"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Biocine", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "UW - Seattle AVEG": "47.606 -122.332", 
        "Univ. of Rochester AVEG": "43.161 -77.611", 
        "Vanderbilt Univ. Hosp. AVEG": "36.166 -86.784"
    }
}